The Technical Analyst
Moderna Inc [MRNA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Moderna Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.89% $108.85
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 41 676 mill |
| EPS: | -12.33 |
| P/E: | -8.83 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 382.88 mill |
| Avg Daily Volume: | 3.76 mill |
| RATING 2024-04-23 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.83 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.50x |
| Company: PE -8.83 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-70.48 (-164.75%) $-179.33 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 104.01 - 113.69 ( +/- 4.44%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-17 | Afeyan Noubar | Sell | 8 243 | Common Stock |
| 2024-04-17 | Afeyan Noubar | Sell | 6 475 | Common Stock |
| 2024-04-17 | Afeyan Noubar | Sell | 282 | Common Stock |
| 2024-04-15 | Hoge Stephen | Sell | 15 000 | Common Stock |
| 2024-04-10 | Afeyan Noubar | Sell | 6 351 | Common Stock |
| INSIDER POWER |
|---|
| 31.48 |
| Last 100 transactions |
| Buy: 525 652 | Sell: 276 824 |
Forecast:
16:00 - $108.97
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $108.97
Forecast 2: 16:00 - $108.97
Forecast 3: 16:00 - $108.97
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $108.85 (0.89% ) |
| Volume | 3.39 mill |
| Avg. Vol. | 3.76 mill |
| % of Avg. Vol | 90.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRNA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $95.30 | N/A | Active |
|---|
MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-24 08:00:00 - Press Release
Moderna And Openai Collaborate To Advance Mrna Medicine
Generative ai will help advance moderna's broad and diverse portfolio to maximize the company's impact on patients moderna embeds openai's generative ai tools throughout its organization and sees early success with broad adoption of chatgpt enterprise cambridge, ma and san francisco, ca / accesswire / april 24, 2024 / moderna, inc. (nasdaq:mrna) and openai today announced their ongoing collaboration to co-innovate with a shared vision of ai's transformative potential in the future of business and healthcare. moderna is a digital-first company that has leveraged the power of machine learning since its beginnings.
2024-04-22 07:00:00 - Press Release
Moderna Announces Contract With Brazil To Supply 12.5 Million Covid-19 Vaccines As Part Of National Vaccination Campaign
Cambridge, ma / accesswire / april 22, 2024 / moderna, inc. (nasdaq:mrna) today announced a contract with the ministry of health in brazil (ministÉrio da saÚde) to supply its mrna covid-19 vaccine as an integral part of brazil's 2024 national vaccination campaign against covid-19. this contract follows the brazilian health regulatory agency's (anvisa) approval of moderna's covid-19 vaccine in march 2024, which encodes the spike protein of the xbb.1.5 sublineage of sars-cov-2 for active immunization for the prevention of covid-19 in children from six months of age and adults.
2024-04-17 07:00:00 - Press Release
Moderna To Report First Quarter 2024 Financial Results On Thursday, May 2, 2024
Cambridge, ma / accesswire / april 17, 2024 / moderna, inc. (nasdaq:mrna), today announced that it will host a live conference call and webcast at 8:00 a.m. et on thursday, may 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.
2024-04-11 23:18:00 - Press Release
Moderna Betrays Africa, Says Ahf
Los angeles--(business wire)-- #africa--aids healthcare foundation (ahf) says moderna's promise to build a state-of-the-art mrna manufacturing facility in africa in 2022 was nothing more than a self-serving effort to deflect criticism for price gouging on its covid-19 vaccine after the pharma company announced today that it's suspending the project. “moderna's greed knows no bounds. it raked in $30 billion in profit since 2021. now, it claims the mrna factory in kenya is no longer worth the investment be.
2024-04-03 11:00:00 - Press Release
Phase 1/2 Interim Data On Moderna's Mrna-3927, An Investigational Mrna Therapy For Propionic Acidemia, Published In Nature
Cambridge, ma / accesswire / april 3, 2024 / moderna, inc. (nasdaq:mrna) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mrna-3927, an investigational mrna therapy for propionic acidemia (pa), has been published in nature. "we are excited to share the first published clinical data utilizing an mrna therapy for intracellular protein replacement," said kyle holen, m.d.
Latest News
2024-04-23 13:38:39 - InvestorPlace
Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy
While artificial intelligence may be useful for a variety of purposes – including asking silly questions we're afraid to pose in real life – the ultimate end game for digital intelligence could be to advance the human condition, which brings us to medical AI stocks. When conducted in a controlled environment, AI can help accelerate productivity.
2024-04-23 07:21:40 - Reuters
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.
2024-04-17 07:00:00 - Accesswire
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.
2024-04-16 10:05:40 - Zacks Investment Research
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
2024-04-16 04:55:00 - The Motley Fool
2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential
AI could solve one of the biggest problems in drug development: the lengthy time it takes to bring a product to market. The AI in healthcare market is set to expand at a compound annual growth rate of nearly 50%.
2024-04-12 08:45:00 - The Motley Fool
1 New Green Flag for Moderna and Merck Stock
Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.
2024-04-11 19:06:18 - Zacks Investment Research
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.
2024-04-11 14:10:34 - InvestorPlace
3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
2024-04-11 13:49:13 - InvestorPlace
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in value over the past six months, outpacing broader market gains.
2024-04-11 12:16:55 - CNBC
Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint.